

Representative Life Sciences Deals

- \$28.3 Billion in Commitments to more than 700 Companies since 2003
- Total New Debt & Equity Commitments of \$2.74 Billion YTD as of Q2 2026
- Total New Fundings of \$1.35 Billion YTD as of Q2 2026
- Over 1,000 Co-investments with Different VC & PE Firms in the last 20+ Years
- Over 290 Companies completed IPO or M&A Events since Inception



\$150,000,000
Debt Commitment
\$2,937,500
Equity Commitment

Invested in 2026
NASDAQ: MAZE



\$325,000,000
Debt Commitment
\$2,000,000
Equity Commitment

Invested in 2025, 2026
NASDAQ: DYN



\$175,000,000
Debt Commitment

Invested in 2024, 2026
NASDAQ: IRON



\$105,000,000
Debt Commitment

Invested in 2025
NASDAQ: SVRA



\$250,000,000
Debt Commitment
\$2,250,000
Equity Commitment

Invested in 2024, 2025
NYSE: RCUS



\$45,000,000
Debt Commitment

Invested in 2025
NASDAQ: ALT



\$75,000,000
Debt Commitment

Invested in 2026
NASDAQ: LXRX



\$95,000,000
Debt Commitment
\$55,000,000
Royalty Commitment

Invested in 2025, 2026
Private



\$75,000,000
Debt Commitment

Invested in 2024, 2025
Private



\$300,000,000
Debt Commitment

Invested in 2025, 2026
NASDAQ: MLTX



\$150,000,000
Debt Commitment

Invested in 2026
NASDAQ: FDMT



\$130,000,000
Debt Commitment

Invested in 2023, 2026
NASDAQ: CMPS



\$160,000,000
Debt Commitment

Invested in 2019, 2022,
2023, 2026
NASDAQ: REPL



\$195,000,000
Debt Commitment,
Syndicated Royalty
Commitment

Invested in 2021, 2022,
2023, 2026
NASDAQ: PHAT



\$80,000,000
Debt Commitment

Invested in 2023, 2024,
2025, 2026
NASDAQ: SENS



\$150,000,000
Debt Commitment
\$1,500,000
Equity Commitment

Invested in 2013 - 2026
NASDAQ: QURE

Note: Commitments represent total amount of committed capital on the facility, which in select cases includes syndicated amount with partners.

 \$40,000,000 Debt Commitment Invested in 2025 Private	 \$100,000,000 Debt Commitment Invested in 2026 Private	 \$35,000,000 Debt Commitment Invested in 2026 Private	 \$100,000,000 Debt Commitment Invested 2022 NASDAQ: KURA
 \$100,000,000 Debt Commitment Invested in 2021, 2023, 2026 NASDAQ: ENGN	 \$100,000,000 Debt Commitment Invested in 2023 Private	 \$30,000,000 Debt Commitment Invested in 2024 NASDAQ: OBIO	 \$65,000,000 Debt Commitment Invested in 2024 NASDAQ: SGHT
 \$25,000,000 Debt Commitment Invested in 2024 Private	 \$250,000,000 Debt Commitment Invested in 2022, 2023, 2025 NASDAQ: VRDN	 \$190,000,000 Debt Commitment \$1,200,000 Equity Commitment Invested in 2022, 2023 NASDAQ: MDGL	 \$275,000,000 Debt Commitment \$5,000,000 Equity Commitment Invested in 2020, 2021, 2022, 2023 NASDAQ: AXSM
 \$140,000,000 Debt Commitment Invested in 2019, 2021, 2023 NASDAQ: TGTX	 \$100,000,000 Debt Commitment \$2,000,000 Equity Commitment Invested in 2022, 2024 Acquired by Novo Nordisk	 \$75,000,000 Debt Commitment Invested in 2022, 2024 Acquired by Lilly	 \$300,000,000 Debt Commitment Invested in 2023 Acquired by Merck

Note: Commitments represent total amount of committed capital on the facility, which in select cases includes syndicated amount with partners.

Boston Office

R. Bryan Jadot
Sr. Managing Director
and Group Head
617.314.9981
bjadot@htgc.com

Jeff Ralto
Managing Director
857.202.5387
jralto@htgc.com

Michael McMahon
Managing Director
857.206.8964
mmcmahon@htgc.com

Michael Dutra
Sr. Managing Director
& Sr. Investment Officer
617.314.9989
mdutra@htgc.com

New York Office

John Miotti
Principal
347.329.3299
jmiotti@htgc.com

San Mateo Office

Cristy Barnes
Managing Director
650.600.5432
cbarnes@htgc.com

Briana Gironda
Principal
650.600.5421
bgironda@htgc.com

San Diego Office

Lake McGuire
Managing Director
517.304.0382
lmcguire@htgc.com

Denver Office

Tom Hertzberg
Managing Director
719.203.7709
thertzberg@htgc.com

Brian Powers
Managing Director
719.203.7728
bpowers@htgc.com

DC/MD/VA Region

Adam Soller
Managing Director
571.309.1347
asoller@htgc.com